The combination of toripalimab and albumin-bound paclitaxel will be used to treat advanced triple-negative breast cancer. Credit Design_Cells via Shutterstock.com.

China’s National Medical Products Administration (NMPA) has accepted Shanghai Junshi Biosciences’ supplemental new drug application (sNDA) for toripalimab in combination with chemotherapy to treat advanced triple-negative breast cancer (TNBC).

The anti-PD-1 monoclonal antibody toripalimab will be used along with albumin-bound paclitaxel to treat PD-L1 positive (CPS ≥ [greater than or equal to] 1) untreated metastatic or recurrent metastatic TNBC.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It has been developed to block PD-1 interactions with its PD-L1 and PD-L2 ligands and for improved receptor internalisation (endocytosis function).

Junshi Biosciences global research and development president Dr Jianjun Zou stated: “For a very long time, the treatment of advanced TNBC has been incredibly challenging, and TNBC has posed a constant threat to patients’ lives.

“We plan to work closely with regulatory authorities to expedite the approval process and address the unmet needs of countless TNBC patients in China as soon as possible.”

See Also:

The sNDA is based on the data from the TORCHLIGHT trial, which was jointly conducted in 56 centres across the country.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The placebo-controlled, randomised, multi-centre, double-blind Phase III clinical trial was designed to compare the safety and efficacy of toripalimab with albumin-bound paclitaxel against placebo along with albumin-bound paclitaxel in patients with an initial diagnosis of stage IV or recurrent metastatic TNBC.

Data showed that treatment with a combination of toripalimab and albumin-bound paclitaxel significantly prolonged the progression-free survival (PFS) of PD-L1 positive patients compared to albumin-bound paclitaxel alone.

It also improved the overall survival (OS) in both PD-1-positive patients and all other patients, irrespective of their PD-1 status.

Toripalimab’s safety profile was found to be consistent with known checkpoint inhibitor-related risks.